Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Myozyme | Alglucosidase | Pompe's disease | List with clinical criteria and/or conditions | Complete | ||
Praluent | Alirocumab | Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Rasilez | Aliskiren | Hypertension | Do not list | Complete | ||
Toctino | Alitretinoin | Eczema | List with clinical criteria and/or conditions | Complete | ||
Axert | Almotriptan | Migraine | List in a similar manner to other drugs in class | Complete | ||
Nesina | Alogliptin | Diabetes mellitus, type 2 | Do not list | Complete | ||
Kazano | Alogliptin plus metformin | Diabetes mellitus, type 2 | Do not list | Complete | ||
Piqray | alpelisib | Advanced or Metastatic Breast Cancer | Do not reimburse | Complete | ||
Zemaira | Alpha1-proteinase inhibitor (Human) | Severe Alpha1-proteinase inhibitor deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
Volibris | Ambrisentan | Pulmonary arterial hypertension (WHO class II and III) | List with clinical criteria and/or conditions | Complete |